Valuation: Exact Sciences Corporation

Market Cap 20.03B 17.79B 16.63B 15.16B 28.54B 1,928B 28.93B 201B 77.9B 982B 75.19B 73.56B 3,154B P/E 2024
-10.1x
P/E 2025 -92.2x
Enterprise Value 21.6B 19.18B 17.94B 16.35B 30.77B 2,079B 31.2B 217B 84.01B 1,059B 81.08B 79.32B 3,401B EV / Sales 2024
4.4x
EV / Sales 2025 6.42x
Free-Float
98.24%
Yield 2024 *
-
Yield 2025 -
1 day+0.95%
Current year+3.30%
Current year 101.51
Extreme 101.51
104.98
1 year 55.56
Extreme 55.56
104.98
3 years 38.81
Extreme 38.8118
104.98
5 years 29.27
Extreme 29.27
104.98
10 years 13.05
Extreme 13.05
159.54
Date Insider Type Main position Quantity % Market Cap. Importance
3/23/26 Issuer sale

Director

28,899 0.0151%
3/23/26 Free

Executive/Senior Manager

199,374 0.1044%
3/23/26 Issuer sale

Director

20,558 0.0108%
Change 5-day change 1-year change 3-year change Capi.($)
+0.95%-.--%+91.76%+53.78% 20.03B
+4.16%-0.36%+49.37%+94.17% 74.46B
-0.61%+0.81%+27.25%+80.21% 60.14B
-2.54%-1.65%+4.86%+33.32% 48.15B
-2.71%-4.74%+28.55%+35.12% 44.25B
+1.18%+4.04%+353.40%+694.54% 43.99B
-1.57%+0.21%+7.63%+102.08% 41.61B
+3.32%+3.49%+11.18%+51.23% 29.97B
+4.77%+6.16%+36.77%+22.78% 29.31B
-3.38%-8.95%-24.86%+336.22% 24.93B
Average +0.39%+1.77%+58.59%+150.35% 41.68B
Weighted average by Cap. +0.49%+1.74%+60.72%+147.44%

Financials

2024 2025
Net sales 2.76B 2.45B 2.29B 2.09B 3.93B 266B 3.99B 27.72B 10.73B 135B 10.36B 10.13B 435B 3.25B 2.88B 2.7B 2.46B 4.63B 313B 4.69B 32.63B 12.63B 159B 12.19B 11.93B 511B
Net income -1.03B -914M -855M -779M -1.47B -99.06B -1.49B -10.34B -4B -50.45B -3.86B -3.78B -162B -208M -185M -173M -157M -296M -20.02B -300M -2.09B -809M -10.2B -781M -764M -32.75B
Net Debt 1.74B 1.54B 1.44B 1.32B 2.48B 167B 2.51B 17.46B 6.76B 85.21B 6.52B 6.38B 274B 1.57B 1.39B 1.3B 1.19B 2.24B 151B 2.27B 15.78B 6.11B 76.99B 5.9B 5.77B 247B
Logo Exact Sciences Corporation
Exact Sciences Corporation is a provider of cancer screening and diagnostic tests. It offers a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. Its portfolio includes brands such as Cologuard and Oncotype DX, along with solutions like Cancerguard for blood-based analysis of molecular information across multiple cancers and Oncodetect for molecular residual disease and recurrence monitoring. Its flagship screening products, the Cologuard and Cologuard Plus tests, are patient-friendly, non-invasive, stool-based DNA (sDNA) screening tests that utilize a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. Its Cancerguard test is designed to detect multiple cancers in their earliest stages from a single blood draw. It offers predefined genetic tests for all clinically relevant genes, and whole genome (PGnome) sequencing tests.
Employees
7,150
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
AAA
  1. Stock Market
  2. Stocks
  3. EXAS Stock